Shifting from quinine to artesunate as first-line treatment of severe malaria in children and adults: Saving more lives

Journal of Infection and Public Health

Volumn 7, Issue 5, 2014, Pages 407-412

  Noubiap, Jean Jacques N ^a  

^a Internal Medicine Unit Edea Regional Hospital   (Cameroon)

Author keywords

Artesunate; Quinine; Severe malaria

Indexed keywords

ARTESUNATE; QUININE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE;

ABSCESS; ADULT; ADULT DISEASE; ANTIMICROBIAL THERAPY; ARTICLE; BLINDNESS; CARDIOTOXICITY; CHILD; CHILDHOOD DISEASE; COMA; CONTROLLED CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEARING IMPAIRMENT; HEART ARRHYTHMIA; HUMAN; HYPOGLYCEMIA; MALARIA; MALARIA CONTROL; META ANALYSIS (TOPIC); NEUTROPENIA; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; TETANUS; TINNITUS; VOMITING; AFRICA; MORTALITY; PRESCHOOL CHILD; SURVIVAL; TREATMENT OUTCOME;

ADULT; AFRICA; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; HEALTH POLICY; HUMANS; MALARIA; QUININE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84926253686     PISSN: 18760341     EISSN: 1876035X     Source Type: Journal    
DOI: 10.1016/j.jiph.2014.04.007     Document Type: Article

References (24)

1. WHO World Malaria Report 2013 2014, Available at: http://www.who.int/malaria/publications/world_malaria_report_2013/report/en/ [accessed 08.05.14].
2. White M.T., Conteh L., Cibulskis R., Ghani A.C. Costs and cost-effectiveness of malaria control interventions - a systematic review. Malar J 2011, 10:337.
3. Saving more lives with artesunate injectable. Injectable Artesunate Stakeholders' Meeting Report 2012, Geneva. Available at: http://www.mmv.org/sites/default/files/uploads/docs/publications/Injectable%20Artesunate%20Stakeholders%20Meeting%20Report.pdf [accessed 12.10.13].
4. WHO Severe and complicated malaria. Trans R Soc Trop Med Hyg 2000, 94(Suppl. 1):S1-S90.
5. WHO Guidelines for the treatment of malaria 2011, World Health Organization, Geneva. 2nd ed. - Rev. 1.
6. Sinclair D., Donegan S., Isba R., Lalloo D.G. Artesunate versus quinine for treating severe malaria. Cochrane Database Syst Rev 2012, 6:CD005967.
7. Guyatt G.H., Oxman A.D., Vist G.E., Kunz R., Falck-Ytter Y., Alonso-Coello P., et al. GRADE: an emerging consens on rating quality evidence and strength of recommendations. BMJ 2008, 336(7650):924-926.
8. Gathu M., Opiyo N., Ogutu B., English M. Artesunate versus quinine for treatment of severe malaria in African children 2013, Available at: http://www.idoc-africa.org/new/images/documents/ETAT/Mini%20review%20-%20artesunate%20versus%20quinine%20for%20severe%20malaria.pdf [accessed 12.10.13].
9. White N.J. The treatment of malaria. N Engl J Med 1996, 335(11):800-806.
10. Mehta U., Durrheim D.N., Blumberg L., Dohohue S., Hansford F., Mabuza A., et al. Malaria deaths as sentinel events to monitor healthcare delivery and antimalarial drug safety. Trop Med Int Health 2007, 12(5):617-628.
11. Yen L.M., Dao L.M., Day N.P., Waller D.J., Bethell D.B., Son L.H., et al. Role of quinine in the high mortality of intramuscular injection tetanus. Lancet 1994, 344(8925):786-877.
12. [accessed 12.10.13]. http://www.mmv.org/sites/default/files/uploads/docs/access/Access_projects/Advantages_of_injectable_artesunate.pdf.
13. Bethell D., Se Y., Lon C., Socheat D., Saunders D., Teja-Isavadharm, et al. Dose-dependent risk of neutropenia after 7-day courses of artesunate monotherapy in Cambodian patients with acute Plasmodium falciparum malaria. Clin Infect Dis 2010, 51(12):e105-e114.
14. Angus B.J., Thaiaporn I., Chanthapadith K., Suputtamongkol Y., White N.J. Oral artesunate dose-response relationship in acute falciparum malaria. Antimicrob Agents Chemother 2002, 46(3):778-782.
15. Bartelink I.H., Rademaker C.M., Schobben A.F., van den Anker J.N. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin. Pharmacokinet 2006, 45:1077-1097.
16. Barnes K.I., Little F., Smith P.J., Evans A., Watkins W.M., White N.J. Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin Pharmacol Ther 2006, 80(6):582-596.
17. Tarning J., Zongo I., Some F.A., Rouamba N., Parikh N., Rosenthal P.J., et al. Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin Pharmacol Ther 2012, 91(3):497-505.
18. Hendriksen I.C., Mtove G., Kent A., Gesase S., Reyburn H., Lemnge M.M., et al. Population pharmacokinetics of intramuscular artesunate in African children with severe malaria: implications for a practical dosing regimen. Clin Pharmacol Ther 2013, 93(5):443-450.
19. Lubell Y., Riewpaiboon A., Dondorp A.M., von Seidlein L., Mokuolo O.A., Nansumba M., et al. Cost-effectiveness of parenteral artesunate for treating children with severe malaria in sub-Saharan Africa. Bull World Health Organ 2011, 89(7):504-512.
20. Naidoo P., Saman S. Artesunate vs. quinine for severe malaria. S Afr Med J 2013, 103(5):274.
21. Medicines for Malaria Venture Request for proposal (RFP) - MMV-2013-PA injectable artesunate 2013, http://www.mmv.org/sites/default/files/uploads/docs/jobs/MMV_RFP_for_Procurement_Agent_injectable_artesunate.pdf [accessed 12.10.13].
22. Medicines for Malaria Venture Injectable artesunate tool kit 2014, http://www.mmv.org/sites/default/files/uploads/docs/access/Injectable_Artesunate_Tool_Kit/PosterInjectableArtesunate.pdf [accessed 08.05.14].
23. Zurovac D., Sudoi R.K., Akhwale W.S., Ndiritu M., Hamer D.H., Rowe A.K., et al. The effect of mobile phone text-message reminders on Kenyan health workers' adherence to malaria treatment guidelines: a cluster randomised trial. Lancet 2011, 378(9793):795-803.
24. Zurovac D., Larson Bam Sudoi R.K., Snow R.W. Costs and cost-effectiveness of a mobile phone text-message reminder programmes to improve health workers' adherence to malaria guidelines in Kenya. PLoS ONE 2012, 7(12):e52045.